Vietnam to welcome cell stem quality control centre meeting international standards

This MoU forms a partnership between the two organisations in which Cyto-Facto Inc will provide training, consulting, and technology in cell and stem cell production (including mesenchymal stem cell production from knee synovial membrane) following Japanese quality control standards.

The signing ceremony between Hoa Lam Shangri-La Healthcare and Cyto-Facto Inc

They will also provide consultative support in implementing automated cell and stem cell processing systems for Hoa Lam Shangri-La Healthcare Park.

In addition, Cyto-Facto Inc is going to consult on establishing a quality control centre adhering to international standards, for Hoa Lam Shangri-La Healthcare Park.

This collaboration is expected to further advance the development of Hoa Lam Shangri-La Healthcare Park, particularly in stem cell and regenerative medicine.

Currently, stem cells are widely utilised in regenerative medicine and chronic disease treatment.

Vietnam’s healthcare sector has successfully implemented hematopoietic stem cell transplantation (bone marrow transplants) in treating blood cancer and using adipose-derived stem cells for knee osteoarthritis treatment, applying stem cells for cardiovascular disease treatment as well as chronic obstructive pulmonary disease.

International collaboration in stem cell research, development, and application, particularly with Japan – renowned as the “cradle” of cellular technology with three Nobel Prizes in Biomedical – will provide enhanced healthcare opportunities for millions of Vietnamese patients suffering from chronic and severe illnesses.

The MoU signing ceremony between Hoa Lam Shangri-La Healthcare and Cyto-Facto Inc

Cyto-Facto Inc is the first company to separate from the Foundation for Biomedical Research and Innovation at Kobe – a core organisation within the Kobe Biomedical Innovation Cluster, Japan's largest life sciences and biomedical cluster.

Cyto-Facto Inc has accumulated extensive manufacturing technology experience and has implemented production lines for stem cells and immune cells, including Chimeric Antigen Receptor T-cells, Induced Pluripotent Stem Cells, and Mesenchymal Stem Cells at various developmental stages.

Notably, Cyto-Facto Inc is recognised as Asia’s first company to manufacture commercial CAR-T products under the Good Manufacturing Practices standards of the Pharmaceutical Inspection Co-operation Scheme.

Vietnam hailed for wise investment in health care Wise investment in health care is one of the factors leading to Vietnam’s spectacularly effective COVID-19 response, said an article published on the Japan Times on July 26.

HCM City welcomes volunteers to relieve overwhelmed health care system More than 1,300 people in Ho Chi Minh City have signed up to volunteer for the fight against the outbreak of the highly infectious Delta variant following an appeal letter from Deputy Minister of Health Nguyen Truong Son.

Digital transformation in health care - irreversible trend An official of the Ministry of Health has called digital transformation in health care an irreversible trend.